Nexien BioPharma (NXEN) 10-Q 10 Nov 20 2021 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Sep. 30, 2020	Nov. 10, 2020
Cover [Abstract]
Entity Registrant Name	NEXIEN BIOPHARMA, INC.
Entity Central Index Key	0001625288
Document Type	10-Q
Document Period End Date	Sep. 30, 2020
Amendment Flag	false
Current Fiscal Year End Date	--06-30
Entity Reporting Status Current	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		55,781,196
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2021

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Sep. 30, 2020	Jun. 30, 2020
Current Assets
Cash	$ 8,202	$ 10,786
Prepaid expenses	9,000	12,000
Total current assets	17,202	22,786
Total Assets	17,202	22,786
Current Liabilities
Accounts payable and accrued expenses	24,682	17,151
Convertible note payable - related		12,000
Total current liabilities	24,682	29,151
Commitments and Contingencies
Stockholders' Deficit
Preferred stock, $.0001 par value; 10,000,000 authorized; none issued
Common stock-$.0001 par value; 200,000,000 shares authorized; 55,781,196 shares issued and outstanding -September 30, 2020; 53,984,004 shares issued and outstanding -June 30, 2020;	5,578	5,398
Additional paid in capital	11,856,284	11,583,159
Common stock subject to forfeiture	(2,360,766)	(3,147,763)
Accumulated deficit	(9,508,576)	(8,447,159)
Total Stockholders' Deficit	(7,480)	(6,365)
Total Liabilities and Stockholders' Deficit	$ 17,202	$ 22,786

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2020	Jun. 30, 2020
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	55,781,196	53,984,004
Common stock, shares outstanding	55,781,196	53,984,004

Consolidated Statements of Oper

Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Income Statement [Abstract]
Revenue
Operating expenses
Professional fees	15,590	23,936
General and administrative	1,045,699	682,966
Impairment of license fees		35,000
Total operating expenses	1,061,289	741,902
Other expense
Interest expense - related	128
Total other expense	128
Net loss	$ (1,061,417)	$ (741,902)
Loss per share - basic and diluted	$ (0.02)	$ (0.01)
Weighted average shares outstanding - basic and diluted	54,951,723	53,698,615

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Deficit (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid in Capital [Member]	Common Stock Subject to Forfeiture [Member]	Accumulated Deficit [Member]	Total
Balance at Jun. 30, 2019	$ 5,351	$ 11,505,819	$ (5,469,708)	$ (5,775,542)	$ 265,920
Balance shares at Jun. 30, 2019	53,510,718
Issuance of stock for accounts payable at $0.09 per share	$ 1	1,499			1,500
Issuance of stock for accounts payable at $0.09 per share, shares	16,667
Issuance of stock for license at $0.09 per share	$ 38	34,962			35,000
Issuance of stock for license at $0.09 per share, shares	381,619
Issuance of stock for services at $0.10 per share	$ 8	7,492			7,500
Issuance of stock for services at $0.10 per share, shares	75,000
Vesting of management shares subject to forfeiture			18,750		18,750
Fair value of options and warrants issued for services		17,848			17,848
Amortization of CRx shares			578,945		578,945
Net loss				(741,902)	(741,902)
Balance at Sep. 30, 2019	$ 5,398	11,567,620	(4,872,013)	(6,517,444)	183,561
Balance shares at Sep. 30, 2019	53,984,004
Balance at Jun. 30, 2019	$ 5,351	11,505,819	(5,469,708)	(5,775,542)	265,920
Balance shares at Jun. 30, 2019	53,510,718
Balance at Jun. 30, 2020	$ 5,398	11,583,159	(3,147,763)	(8,447,159)	(6,365)
Balance shares at Jun. 30, 2020	53,984,004
Issuance of stock for conversion of related party note payable and interest at $0.014 per share	$ 180	24,981			25,161
Issuance of stock for conversion of related party note payable and interest at $0.014 per share, shares	1,797,192
Fair value of options granted		248,144			248,144
Amortization of CRx shares			786,997		786,997
Net loss				(1,061,417)	(1,061,417)
Balance at Sep. 30, 2020	$ 5,578	$ 11,856,284	$ (2,360,766)	$ (9,508,576)	$ (7,480)
Balance shares at Sep. 30, 2020	55,781,196

Consolidated Statements of St_2

Consolidated Statements of Stockholders' Deficit (Unaudited) (Parenthetical) - $ / shares	Sep. 30, 2020	Sep. 30, 2019
License [Member]
Shares issued price, per share		$ 0.09
Services [Member]
Shares issued price, per share		0.10
Accounts Payable [Member]
Shares issued price, per share		$ 0.09
Related Party Notes Payable and Interest [Member]
Shares issued price, per share	$ 0.014

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Cash flows from operating activities
Net loss	$ (1,061,417)	$ (741,902)
Adjustments to reconcile net loss to net cash used in operating activities
Stock based compensation	248,144	36,598
Fair value of shares issued for CRx Acquisition	786,997	578,945
Stock issued for services and license fee		42,500
Changes in assets and liabilities
Decrease in prepaids	3,000	29,324
Increase (decrease) in accounts payable and accrued expenses	7,692	(21,000)
Cash used in operating activities	(15,584)	(75,535)
Cash flows from investing activities
Cash used in investing activities
Cash flows from financing activities
Cash proceeds from convertible note payable - related party	13,000
Cash provided by financing activities	13,000
Net increase in cash and cash equivalents	(2,584)	(75,535)
Cash and cash equivalents, beginning of period	10,786	146,356
Cash and cash equivalents, end of period	8,202	70,821
Supplemental disclosure of non-cash investing and financing activities
Shares issued for conversion of related party note and interest	25,161
Shares issued for settlement of accounts payable		$ 1,500

Nature of Business and Basis of

Nature of Business and Basis of Presentation	3 Months Ended
	Sep. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Business and Basis of Presentation	Note 1 – Nature of Business and Basis of Presentation The Company was incorporated on November 10, 1952 in Michigan as Gantos, Inc. On July 21, 2008, the Company completed its change in domicile to Delaware and subsequently changed its name to Kinder Holding Corp. (the “Company”). As of October 13, 2017, the Company completed a reverse acquisition of Intiva BioPharma Inc., a Colorado corporation (“BioPharma”) through an exchange of shares (the “Share Exchange Transaction”). In connection with the Share Exchange Transaction, the Company changed its name to Intiva BioPharma Inc. on November 8, 2017 and, in September 2018, the Company changed its name to Nexien BioPharma, Inc. As further described in Note 4, BioPharma became a wholly-owned subsidiary of the Company. Since this transaction resulted in the existing shareholders of BioPharma acquiring control of the Company, for financial reporting purposes, the business combination has been accounted for as an additional capitalization of the Company (a reverse acquisition with BioPharma as the accounting acquirer). The operations of BioPharma were the only continuing operations of the Company. The accompanying financial statements as of September 30, 2020 and June 30, 2020, and for the three months and year then ended, present the historical financial information of BioPharma. BioPharma was incorporated under the laws of the State of Colorado on March 27, 2017 to pursue pre-clinical and drug development activities, in accordance with U.S. Food and Drug Administration (“FDA”) protocols, for certain pharmaceutical formulations that include cannabinoids. It is pursuing the formulation and development of drugs containing cannabinoids for the treatment of various diseases, disorders and medical conditions, and owns a license covering certain intellectual property, including certain patent applications, and has filed three of its own provisional patent applications for other drugs that include cannabinoids and other substances, including terpenes, that are intended to be developed with the objective of treating certain medical conditions and disorders. It was formed as a corporate subsidiary of the Colorado corporation Kanativa USA Inc. (“Kanativa USA”), which is a subsidiary of the Ontario, Canada corporation, Kanativa Inc. Principles of Consolidation The accompanying consolidated financial statements include BioPharma and its wholly owned subsidiaries: Intiva BioPharma Inc. (a Colorado corporation), NexN Inc. (“NexN”) and NexDM Inc. (collectively the “Company”), and were prepared from the accounts of the Company in accordance with accounting principles generally accepted in the United States of America (US GAAP). All significant intercompany transactions and balances have been eliminated on consolidation. All share and per share amounts have been adjusted in the footnotes and accompanying financial statements to give effect to the Share Exchange Transaction. (See Note 4).

Going Concern Uncertainty

Going Concern Uncertainty	3 Months Ended
	Sep. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern Uncertainty	Note 2 - Going Concern Uncertainty The accompanying financial statements have been prepared in conformity with US GAAP, which contemplates continuation of the Company as a going concern. The Company has not established any source of revenue to cover its operating costs, and as such, has incurred an operating loss since inception of $9,508,576. The development of pharmaceuticals with the objective of obtaining approval by the FDA and other international regulatory authorities is not a short-term endeavor for any specific drug candidate. It also requires extremely significant amounts of capital funding for clinical trials and other matters. At September 30, 2020, the Company had a working capital deficit of $7,480. The Company will require significant additional capital to fund the implementation and execution of its business plan. This capital, which likely will be millions of dollars for a single drug candidate, will be required for research, regulatory applications, and clinical trials. At the present time, the Company does not have any commitments or known sources for this level of funding. These and other factors raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the possible inability of the Company to continue as a going concern.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Sep. 30, 2020
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 3 – Summary of Significant Accounting Policies Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statement and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from the estimates. Cash and Cash Equivalents For financial statement presentation purposes, the Company considers those short-term, highly liquid investments with original maturities of three months or less to be cash or cash equivalents. There were no cash equivalents at September 30, 2020 and June 30, 2020. Valuation of Long-Lived Assets The Company reviews the recoverability of its long-lived assets including equipment, goodwill and other intangible assets, when events or changes in circumstances occur that indicate that the carrying value of the asset may not be recoverable. The assessment of possible impairment is based on the Company’s ability to recover the carrying value of the asset from the expected future pre-tax cash flows (undiscounted and without interest charges) of the related operations. If these cash flows are less than the carrying value of such asset, an impairment loss is recognized for the difference between estimated fair value and carrying value. The Company’s primary measure of fair value is based on discounted cash flows. The measurement of impairment requires management to make estimates of these cash flows related to long-lived assets, as well as other fair value determinations. Fair Value of Financial Instruments FASB ASC 825, “Financial Instruments,” requires entities to disclose the fair value of financial instruments, both assets and liabilities recognized and not recognized on the balance sheet, for which it is practicable to estimate fair value. FASB ASC 825 defines fair value of a financial instrument as the amount at which the instrument could be exchanged in a current transaction between willing parties. At September 30, 2020 and June 30, 2020, the carrying value of certain financial instruments (cash and cash equivalents, accounts payable and accrued expenses) approximates fair value due to the short-term nature of the instruments or interest rates, which are comparable with current rates. Fair Value Measurements The Company measures fair value under a framework that utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurements) and the lowest priority to unobservable inputs (level 3 measurements). The three levels of inputs which prioritize the inputs used in measuring fair value are: Level 1: Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets that the Company has the ability to access. Level 2: Inputs to the valuation methodology include: ● Quoted prices for similar assets or liabilities in active markets; ● Quoted prices for identical or similar assets or liabilities in inactive markets; ● Inputs other than quoted prices that are observable for the asset or liability; ● Inputs that are derived principally from or corroborated by observable market data by correlation or other means. If the asset or liability has a specified (contractual) term, the level 2 input must be observable for substantially the full term of the asset or liability. Level 3: Inputs to the valuation methodology are unobservable and significant to the fair value measurement. The asset’s or liability’s fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Valuation techniques used need to maximize the use of observable inputs and minimize the use of unobservable inputs. When the Company changes its valuation inputs for measuring financial assets and liabilities at fair value, either due to changes in current market conditions or other factors, it may need to transfer those assets or liabilities to another level in the hierarchy based on the new inputs used. The Company recognizes these transfers at the end of the reporting period that the transfers occur. For the periods ended September 30, 2020 and June 30, 2020, there were no significant transfers of financial assets or financial liabilities between the hierarchy levels. As at September 30, 2020 and June 30, 2020, no assets or liabilities were required to be measured at fair value on a recurring basis. Earnings per Common Share The Company computes net income (loss) per share in accordance with ASC 260, Earning per Share. ASC 260 requires presentation of both basic and diluted earnings per share (EPS) on the face of the income statement. Basic EPS is computed by dividing net income (loss) available to common shareholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method and convertible preferred stock using the if-converted method. In computing Diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. Diluted EPS excludes all dilutive potential shares if their effect is anti-dilutive. Income Taxes The Company has adopted ASC 740, Accounting for Income Taxes. Pursuant to ASC 740, the Company is required to compute tax asset benefits for net operating losses carried forward. The potential benefits of net operating losses have not been recognized in these financial statements because the Company cannot be assured it is more likely than not it will utilize the net operating losses carried forward in future years. Revenue Recognition The Company has adopted ASC 606 — Revenue from Contracts with Customers. Under ASC 606, the Company recognizes revenue from the commercial sales of products, licensing agreements and contracts to perform pilot studies by applying the following steps: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation is satisfied. Research and Development Expenses Research and development expenses are charged to operations as incurred. Concentrations of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. Cash and cash equivalents are deposited with major banks in the United States of America. Management believes that such financial institutions are financially sound and, accordingly, minimal credit risk exists with respect to these financial instruments. The Company does not have any significant off-balance-sheet concentration of credit risk. Stock-based compensation Pursuant to FASB ASC 718, all share-based payments to employees, including grants of employee stock options, are recognized in the statement of operations based on their fair values. Issuance of shares for non-cash consideration The Company accounts for the issuance of equity instruments to acquire goods and/or services based on the fair value of the goods and services or the fair value of the equity instrument at the time of issuance, whichever is more reliably determinable. The Company’s accounting policy for equity instruments issued to consultants and vendors in exchange for goods and services follows the provisions of the standards issued by the FASB. The measurement date for the fair value of the equity instruments issued is determined as the earlier of (i) the date at which a commitment for performance by the consultant or vendor is reached or (ii) the date at which the consultant or vendor’s performance is complete. In the case of equity instruments issued to consultants, the fair value of the equity instrument is recognized over the term of the consulting agreement. Reclassifications Certain amounts in the consolidated financial statements for prior year periods have been reclassified to conform with the current period presentation. Recent Accounting Pronouncements Although there are several other new accounting pronouncements issued or proposed by the FASB, which the Company has adopted or will adopt, as applicable, the Company does not believe any of these accounting pronouncements has had or will have a material impact on its consolidated financial position or results of operations. Management has evaluated accounting standards and interpretations issued but not yet effective as of September 30, 2020 and does not expect such pronouncements to have a material impact on the Company’s financial position, operations, or cash flows.

Share Exchange Agreement

Share Exchange Agreement	3 Months Ended
	Sep. 30, 2020
Business Combinations [Abstract]
Share Exchange Agreement	Note 4 – Share Exchange Agreement On August 8, 2017, the Company entered into a Share Exchange Agreement, as amended and restated on October 13, 2017, (the “Agreement”), with BioPharma. Pursuant to the terms of the Agreement, the Company agreed to issue to the shareholders of BioPharma 42,642,712 post-reverse stock-split shares of the Company’s common stock, par value $0.0001 (“Common Stock”), in exchange for all of the issued and outstanding shares of BioPharma capital stock, thereby making BioPharma a wholly-owned subsidiary of the Company. As part of the Closing of the Agreement, the 20,000,000 pre-reverse split shares of the Company’s Common Stock previously purchased by Kanativa USA, effective on June 26, 2017 in a change in control transaction from the Company’s control shareholders, were canceled. Since this transaction resulted in the existing shareholders of BioPharma acquiring control of the Company, for financial reporting purposes, the business combination has been accounted for as an additional capitalization of the Company (a reverse acquisition with BioPharma as the accounting acquirer).

License Agreements

License Agreements	3 Months Ended
	Sep. 30, 2020
License Agreements
License Agreements	Note 5 – License Agreements Kotzker License Agreement In March 2017, the Company licensed certain intellectual property from Kotzker Consulting LLC (“Kotzker Consulting”), an unrelated entity. The licensed intellectual property includes patent applications relating to the use of cannabinoid receptor modulators and terpenes in the acute treatment during exposure to organophosphorus nerve agents and/or organophosphorus insecticides. Under terms of the agreement, the Company shall use its commercially reasonable efforts to develop and commercialize the licensed products, and, in particular, will be responsible for the design, manufacturing, preclinical, clinical, and regulatory development activities of the licensed products and shall bear the costs of such activities. As consideration for entering into the agreement, the Company agreed to: (i) pay Kotzker Consulting $180,000, (ii) pay patent prosecution costs incurred as of the date of the agreement of $15,000 and (iii) issue to Kotzker Consulting 31,550 shares of Kanativa Inc.’s common stock valued at $78,875 ($2.50 per share based on recent private placement to third parties of Kanativa Inc.’s common stock). The Company has also capitalized legal fees of $29,040 incurred in conjunction with acquiring the license agreement. The license agreement terminates, on a country by country basis, upon the expiration of the licensed patent for the licensed intellectual property, or when a competitor generic product utilizing the licensed technology is marketed in the particular country. The Company shall be responsible for development milestone payments for (i) licensed products for use as a preventative and therapeutic neuroprotective against nerve agents and pesticides and (ii) licensed products for treatment of diseases. Milestone payments for each of the foregoing will each be due in two payments, the first payment no later than thirty (30) days from acceptance of submission of the regulatory filing of the first licensed product and the second payment no later than thirty (30) days from approval of the first licensed product. Royalties will be due beginning with first commercial sale of developed products. The Company has completed and submitted a Pre-Investigational New Drug meeting request and amendment thereto with the FDA. In September 2017, the Company entered into a contract with a contract manufacturing organization to develop an injectable formulation of a drug product to be submitted to the FDA. It is anticipated that the product will be developed utilizing the new drug application 505(b) (2) regulatory pathway for use in the treatment during and immediately following exposure to organophosphorous nerve agents. The drug product is to consist of a synthetic cannabinoid and a blend of terpenes in an injectable vehicle. Accu-Break License Agreement On February 28, 2018, the Company obtained a worldwide exclusive license with respect to a proprietary delivery system for cannabinoid-based medications from Accu-Break Pharmaceuticals Inc (Accu-Break). Upon execution of the agreement, as amended September 18, 2018, $35,000 was paid to the licensor; an additional $30,000 was paid in cash during the year ended June 30, 2019; and a final payment of $35,000 was paid in common stock of the Company during the year ended June 30, 2020. The Company is required to pay milestone payments upon obtaining regulatory approval of pharmaceutical licensed products and royalties based upon sales of licensed products. The Company may grant sublicenses under the terms of the agreement. Write-off of Licenses The Company has previously estimated that it may not be able to recover the $302,915 carrying value of costs capitalized under the Kotzker License Agreement, nor the $65,000 of costs capitalized under the Accu-Break License Agreement, and recognized an impairment of $367,915 for both licenses at June 30, 2019. The $35,000 value of common stock issued in the year ended June 30, 2020 was charged to operations. Although the Company has recognized an impairment under Generally Accepted Accounting Principles, it retains its rights under both of these license agreements.

Stockholders' Equity

Stockholders' Equity	3 Months Ended
	Sep. 30, 2020
Equity [Abstract]
Stockholders' Equity	Note 6– Stockholders’ Equity Common stock During the year ended June 30, 2020 the Company issued 473,286 shares of its common stock as follows: ● 16,667 shares, valued at $1,500 ($0.09 per share), as consideration for consulting services rendered. ● 75,000 shares, valued at $7,500 ($0.10 per share), as partial consideration for entering into an investor relations contract. ● 381,619 shares, valued at $35,000 ($0.092 per share), for final payment on the license agreement with respect to a proprietary delivery system for cannabinoid-based medications (See Note 5). During the three months ended September 30, 2020, the Company issued 1,797,192 shares of its common stock, at $0.014 per share, to its CEO for conversion of a note payable in the principal amount of $25,000 and accrued interest of $161. CRX Limited Liability Company Interest Purchase Agreement On October 26, 2018, Company entered into a Limited Liability Company Interest Purchase Agreement (the “Purchase Agreement”) with the members of CRX Bio Holdings LLC, a Delaware limited liability company (“CRX”), to acquire all of the membership interest in CRX in exchange for 11,000,000 restricted shares of the Company’s common stock (the “Acquisition”), valued at $0.76 per share. The transaction has been accounted for as an asset acquisition, and not a business combination, and has been valued at the fair value of the common stock issued by the Company, as CRX’s cost basis was $0 in the assets. CRX is engaged in the research and development of advanced cannabinoid formulations and drug delivery systems with a focus on bioavailability and related pharmacokinetics and pharmacodynamics (PK/PD) enhancement. The Acquisition transaction was consummated on October 26, 2018. By acquiring CRX as a wholly-owned subsidiary, the Company acquired all of its assets, which consist primarily of three U.S. provisional patent applications relating to cannabinoid formulations to treat convulsive disorders, chronic traumatic encephalopathy, and neuropathic pain. At the closing, the Company issued to the six members of CRX (the “Sellers”) 1,100,000 shares not subject to any forfeiture restrictions and 9,900,000 shares which shall be released from forfeiture restrictions according to the following vesting schedule: ● 30% shall be fully vested 12 months following the Closing (October 26, 2019); ● 30% shall be fully vested 24 months following the Closing (October 26, 2020); ● 30% shall be fully vested 36 months following the Closing (October 26, 2021). Any Seller who is not then providing services to the Company or any of its subsidiaries on any vesting date, whether through voluntary termination or termination “for cause,” will forfeit his unvested shares, which will be cancelled. The transaction has been valued at $8,360,000, based on the fair value of the 11,000,000 shares issued of $0.76 per share, as per the closing market price of the Company’s common stock on the date of the agreement. The $836,000 fair value of the 1,100,000 shares issued not subject to any forfeiture restrictions was charged to operations during the six months ended December 31, 2018. The $7,524,000 fair value of the 9,900,000 shares subject to forfeiture has been charged to stockholders’ equity as a contra equity account, and is being amortized over the vesting periods. The net amount charged to stockholder’s equity was $0 on the date of the acquisition. As at September 30, 2020 and June 30, 2020, an aggregate $4,574,234 and $3,787,237, respectively, has been charged to operations for the value of vested shares issued and the amortization of the unvested CRX shares. For the three months ended September 30, 2020 and 2019, $786,997 and $578,945, respectively, has been charged to operations for the amortization of unvested CRX shares during each of the periods. 2017 Stock Incentive Plan On August 10, 2017, the Company adopted the “2017 Stock Incentive Plan” and granted an aggregate of 6,400,000 shares of Common Stock to five officers and directors of the Company, valued at $800,000 ($0.125 per share). In March 2018, 1,166,667 unvested shares (valued at $145,833) previously issued to the Company’s former Chief Executive Officer were canceled. On July 25, 2018, the Company accelerated the vesting of 1,083,342 unvested shares of Common Stock previously granted to its’ former Chief Executive Officer and Chief Financial Officer. As of June 30, 2020, all 5,233,333 shares issued (valued at $654,167) have been vested, of which 150,000 shares, valued at $18,750, were vested during the year ended June 30, 2020. 2018 Equity Incentive Plan (i) On March 30, 2018, the Company’s board of directors approved and recommended for adoption by the stockholders of the Company a 2018 Equity Incentive Plan and has reserved 8,000,000 shares of Common Stock for issuance under the terms of that Plan. In July 2018, the Board of Directors granted options to purchase a total of 1,810,000 shares of Common Stock, exercisable for a period of seven years, to officers/directors/consultants of the Company at an exercise price of $0.54 per share. In August 2018, the Board of Directors granted options to purchase a total of 150,000 shares of Common Stock, exercisable for a period of seven years, to two individuals, (i) a director and (ii) a consultant of the Company, at an exercise price of $0.38 per share. The fair value of each option grant is estimated on the date of grant using the Black-Scholes option pricing model with the following weighted-average assumptions used for grants under the fixed option plan: Average risk-free interest rates 2.3% - 2.8 % Average expected life (in years) 4.0 to 7.0 Volatility 160% to 296 % The fair value of the options granted at June 30, 2020 is $867,715, including $33,307 for the fair value of options vested in 2020. All options granted have been fully vested as of June 30, 2020. (ii) On October 17, 2018, the Board of Directors granted options to purchase an aggregate 800,000 shares of Common Stock, exercisable for a period of seven years, to officers/directors of the Company at an exercise price of $0.655 per share and confirmed a grant of options made as of October 1, 2018, to purchase 500,000 shares of Common Stock, exercisable for a period of seven years, to an officer and director of the Company at an exercise price $0.48. All of the options were fully vested as of the date of grant. The fair value of each option grant is estimated on the date of grant using the Black-Scholes option pricing model with the following weighted-average assumptions used for grants under the fixed option plan: Average risk-free interest rates 2.88% - 2.93 % Average expected life (in years) 4.0 Volatility 171% to 172 % The fair value of the fully vested options granted of $803,997 was charged to operations during the year ended June 30, 2019. 2018 Equity Incentive Plan (continued) (iii) On August 19, 2020, the Board of Directors authorized the issuance of an aggregate 5,000,000 options to three officers of the Company, exercisable at $0.08 per share for a seven-year period from the date of grant. As of the date of grant, 3,333,334 options were fully vested and the balance of 1,666,666 options will vest quarterly over the next four calendar quarters beginning September 30, 2020. The fair value of each option grant is estimated on the date of grant using the Black-Scholes option pricing model with the following weighted-average assumptions used for grants under the fixed option plan: Average risk-free interest rates .23 % Average expected life (in years) 4.0 Volatility 152 % The fair value of the vested options granted of $248,144 was charged to operations during the three months ended September 30, 2020. A summary of option activity during the three months ended September 30, 2020 is presented below: Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Life (Years) Outstanding and exercisable – June 30, 2020 2,995,000 $ 0.55 5.2 Granted 5,000,000 $ 0.08 6.9 Exercised - Expired/Canceled - Outstanding– September 30, 2020 7,995,000 $ 0.26 5.5 Exercisable – September 30, 2020 6,745,001 $ 0.31 5.5

Convertible Note Payable -Relat

Convertible Note Payable -Related Party	3 Months Ended
	Sep. 30, 2020
Debt Disclosure [Abstract]
Convertible Note Payable -Related Party	Note 7 – Convertible Note Payable -Related Party On June 11, 2020, the Company entered into a financing arrangement with its CEO under which he agreed to lend the Company up to $25,000. The note bears interest at 5% per annum and is due upon demand. At the option of the lender, the unpaid principal and interest may be converted, in whole or in part, into shares of the Company’s common stock at the lesser of (i) $0.014, being the closing price of the Company’s common stock as of the date of the note, or (ii) the volume-weighted average price (VWAP) of the Company’s common stock over the ten trading days immediately preceding the Company’s receipt of Notice of Conversion from the lender. As the market price of the Company’s common stock and the VWAP were the same as of the date of the note, no discount for beneficial conversion feature has been recorded. As of June 30, 2020, the lender had advanced $12,000 under the arrangement; and accrued interest of $33 is included in accounts payable and accrued expenses at June 30, 2020. On July 10, 2020, the Company’s CEO loaned the Company an additional $13,000 pursuant to the financing arrangement. On August 12, 2020, the CEO sent notice to the Company that he was electing to convert the outstanding principal of $25,000 and accrued interest of $161 to 1,797,192 shares of common stock at the contractual conversion price of $0.014 per share. No gain or loss was recognized on conversion as the conversion was made under the terms of the note agreement.

Related Party Transactions

Related Party Transactions	3 Months Ended
	Sep. 30, 2020
Related Party Transactions [Abstract]
Related Party Transactions	Note 8 – Related Party Transactions BioPharma was formed as a subsidiary of Kanativa USA, which is a subsidiary of Kanativa Inc. Kanativa USA was issued 24,000,000 shares of BioPharma’s common stock as consideration for its contribution of 100% of the ownership of NexN, and costs and expenses incurred on behalf of BioPharma and NexN in the amount of $201,228. Included in the consideration for the issuance of the common stock is $172,915 of capitalized license agreement costs comprised of (i) the value of Kanativa Inc. common stock issued to Kotzker Consulting of $78,875 and (ii) payments to Kotzker Consulting and legal costs in the aggregate of $94,040 (See Note 5). At June 30, 2017, BioPharma was owed $141,329 from Kanativa USA for advances made by BioPharma on behalf of Kanativa USA in conjunction with the Share Exchange Agreement (See Note 4). As of June 30, 2020, an aggregate $50,662 was repaid by Kanativa USA, including $15,000 and $9,000 during the years ended June 30, 2019 and June 30, 2020, respectively. The remaining balance of $90,667 was due on March 1, 2020. On May 1, 2020, BioPharma and Kanativa USA entered into an agreement extending the due date for payment of the remaining balance to June 30, 2020. Effective June 30, 2020, Kanativa USA determined that it would be unable to pay the remaining balance of the advance. Accordingly, the Company wrote-off the remaining balance of $90,667 as a charge to operations during the period ended June 30, 2020. On August 10, 2017, the Company granted an aggregate of 6,400,000 shares of Common Stock to five officers and directors of the Company, valued at $800,000 ($0.125 per share), under the Company’s 2017 Stock Incentive Plan. One-third of each grant vested as of the initial date of grant (August 10, 2017), and 8-1/3% upon the end of each calendar quarter beginning December 31, 2017. In March 2018, the Company cancelled 1,166,667 unvested shares previously issued to its former CEO. As of June 30, 2020, all granted shares, valued at $654,167, were fully vested. In February 2018, the Company entered into an exclusive license agreement with Accu-Break whose President was an affiliate of the Company at the time of the agreement (See Note 5). The members of the Company’s Board of Directors, its Chief Executive Office and its Chief Financial Officer are also directors and officers of Kanativa Inc., and other subsidiaries and affiliated entities of Kanativa Inc.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Sep. 30, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 9- Commitments and Contingencies At September 30, 2020, there were no legal proceedings against the Company.

Subsequent Event

Subsequent Event	3 Months Ended
	Sep. 30, 2020
Subsequent Events [Abstract]
Subsequent Event	Note 10 – Subsequent Event On October 2, 2020, the Company’s CEO advanced $15,000 for working capital purposes. The advance is non-interest bearing and is repayable upon demand. The Company has analyzed its operations subsequent to September 30, 2020 through the date these financial statements were issued, and has determined that it does not have any additional material subsequent events to disclose.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Sep. 30, 2020
Accounting Policies [Abstract]
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statement and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from the estimates.
Cash and Cash Equivalents	Cash and Cash Equivalents For financial statement presentation purposes, the Company considers those short-term, highly liquid investments with original maturities of three months or less to be cash or cash equivalents. There were no cash equivalents at September 30, 2020 and June 30, 2020.
Valuation of Long-Lived Assets	Valuation of Long-Lived Assets The Company reviews the recoverability of its long-lived assets including equipment, goodwill and other intangible assets, when events or changes in circumstances occur that indicate that the carrying value of the asset may not be recoverable. The assessment of possible impairment is based on the Company’s ability to recover the carrying value of the asset from the expected future pre-tax cash flows (undiscounted and without interest charges) of the related operations. If these cash flows are less than the carrying value of such asset, an impairment loss is recognized for the difference between estimated fair value and carrying value. The Company’s primary measure of fair value is based on discounted cash flows. The measurement of impairment requires management to make estimates of these cash flows related to long-lived assets, as well as other fair value determinations.
Fair Value of Financial Instruments	Fair Value of Financial Instruments FASB ASC 825, “Financial Instruments,” requires entities to disclose the fair value of financial instruments, both assets and liabilities recognized and not recognized on the balance sheet, for which it is practicable to estimate fair value. FASB ASC 825 defines fair value of a financial instrument as the amount at which the instrument could be exchanged in a current transaction between willing parties. At September 30, 2020 and June 30, 2020, the carrying value of certain financial instruments (cash and cash equivalents, accounts payable and accrued expenses) approximates fair value due to the short-term nature of the instruments or interest rates, which are comparable with current rates.
Fair Value Measurements	Fair Value Measurements The Company measures fair value under a framework that utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurements) and the lowest priority to unobservable inputs (level 3 measurements). The three levels of inputs which prioritize the inputs used in measuring fair value are: Level 1: Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets that the Company has the ability to access. Level 2: Inputs to the valuation methodology include: ● Quoted prices for similar assets or liabilities in active markets; ● Quoted prices for identical or similar assets or liabilities in inactive markets; ● Inputs other than quoted prices that are observable for the asset or liability; ● Inputs that are derived principally from or corroborated by observable market data by correlation or other means. If the asset or liability has a specified (contractual) term, the level 2 input must be observable for substantially the full term of the asset or liability. Level 3: Inputs to the valuation methodology are unobservable and significant to the fair value measurement. The asset’s or liability’s fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Valuation techniques used need to maximize the use of observable inputs and minimize the use of unobservable inputs. When the Company changes its valuation inputs for measuring financial assets and liabilities at fair value, either due to changes in current market conditions or other factors, it may need to transfer those assets or liabilities to another level in the hierarchy based on the new inputs used. The Company recognizes these transfers at the end of the reporting period that the transfers occur. For the periods ended September 30, 2020 and June 30, 2020, there were no significant transfers of financial assets or financial liabilities between the hierarchy levels. As at September 30, 2020 and June 30, 2020, no assets or liabilities were required to be measured at fair value on a recurring basis.
Earnings Per Common Share	Earnings per Common Share The Company computes net income (loss) per share in accordance with ASC 260, Earning per Share. ASC 260 requires presentation of both basic and diluted earnings per share (EPS) on the face of the income statement. Basic EPS is computed by dividing net income (loss) available to common shareholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method and convertible preferred stock using the if-converted method. In computing Diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. Diluted EPS excludes all dilutive potential shares if their effect is anti-dilutive.
Income Taxes	Income Taxes The Company has adopted ASC 740, Accounting for Income Taxes. Pursuant to ASC 740, the Company is required to compute tax asset benefits for net operating losses carried forward. The potential benefits of net operating losses have not been recognized in these financial statements because the Company cannot be assured it is more likely than not it will utilize the net operating losses carried forward in future years.
Revenue Recognition	Revenue Recognition The Company has adopted ASC 606 — Revenue from Contracts with Customers. Under ASC 606, the Company recognizes revenue from the commercial sales of products, licensing agreements and contracts to perform pilot studies by applying the following steps: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation is satisfied.
Research and Development Expenses	Research and Development Expenses Research and development expenses are charged to operations as incurred.
Concentrations of Credit Risk	Concentrations of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. Cash and cash equivalents are deposited with major banks in the United States of America. Management believes that such financial institutions are financially sound and, accordingly, minimal credit risk exists with respect to these financial instruments. The Company does not have any significant off-balance-sheet concentration of credit risk.
Stock-based Compensation	Stock-based compensation Pursuant to FASB ASC 718, all share-based payments to employees, including grants of employee stock options, are recognized in the statement of operations based on their fair values.
Issuance of Shares for Non-cash Consideration	Issuance of shares for non-cash consideration The Company accounts for the issuance of equity instruments to acquire goods and/or services based on the fair value of the goods and services or the fair value of the equity instrument at the time of issuance, whichever is more reliably determinable. The Company’s accounting policy for equity instruments issued to consultants and vendors in exchange for goods and services follows the provisions of the standards issued by the FASB. The measurement date for the fair value of the equity instruments issued is determined as the earlier of (i) the date at which a commitment for performance by the consultant or vendor is reached or (ii) the date at which the consultant or vendor’s performance is complete. In the case of equity instruments issued to consultants, the fair value of the equity instrument is recognized over the term of the consulting agreement.
Reclassifications	Reclassifications Certain amounts in the consolidated financial statements for prior year periods have been reclassified to conform with the current period presentation.
Recent Accounting Pronouncements	Recent Accounting Pronouncements Although there are several other new accounting pronouncements issued or proposed by the FASB, which the Company has adopted or will adopt, as applicable, the Company does not believe any of these accounting pronouncements has had or will have a material impact on its consolidated financial position or results of operations. Management has evaluated accounting standards and interpretations issued but not yet effective as of September 30, 2020 and does not expect such pronouncements to have a material impact on the Company’s financial position, operations, or cash flows.

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	3 Months Ended
	Sep. 30, 2020
Schedule of Fair Value of Stock Options Assumptions	The fair value of each option grant is estimated on the date of grant using the Black-Scholes option pricing model with the following weighted-average assumptions used for grants under the fixed option plan: Average risk-free interest rates .23 % Average expected life (in years) 4.0 Volatility 152 %
Schedule of Stock Option Activity	A summary of option activity during the three months ended September 30, 2020 is presented below: Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Life (Years) Outstanding and exercisable – June 30, 2020 2,995,000 $ 0.55 5.2 Granted 5,000,000 $ 0.08 6.9 Exercised - Expired/Canceled - Outstanding– September 30, 2020 7,995,000 $ 0.26 5.5 Exercisable – September 30, 2020 6,745,001 $ 0.31 5.5
2018 Equity Incentive Plan [Member]
Schedule of Fair Value of Stock Options Assumptions	The fair value of each option grant is estimated on the date of grant using the Black-Scholes option pricing model with the following weighted-average assumptions used for grants under the fixed option plan: Average risk-free interest rates 2.3% - 2.8 % Average expected life (in years) 4.0 to 7.0 Volatility 160% to 296 % The fair value of each option grant is estimated on the date of grant using the Black-Scholes option pricing model with the following weighted-average assumptions used for grants under the fixed option plan: Average risk-free interest rates 2.88% - 2.93 % Average expected life (in years) 4.0 Volatility 171% to 172 %

Going Concern Uncertainty (Deta

Going Concern Uncertainty (Details Narrative) - USD ($)	3 Months Ended
	Sep. 30, 2020	Jun. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Operating loss	$ 9,508,576
Working capital deficit		$ 7,480

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	Sep. 30, 2020	Jun. 30, 2020
Accounting Policies [Abstract]
Cash equivalents

Share Exchange Agreement (Detai

Share Exchange Agreement (Details Narrative) - $ / shares	Aug. 08, 2017	Sep. 30, 2020	Jun. 30, 2020
Common stock par value		$ 0.0001	$ 0.0001
Share Exchange Agreement [Member] | Post-Reverse Stock-Split [Member]
Reverse stock-split shares	42,642,712
Common stock par value	$ 0.0001
Share Exchange Agreement [Member] | Pre-Reverse Split [Member]
Reverse stock-split shares	20,000,000

License Agreements (Details Nar

License Agreements (Details Narrative) - USD ($)	Sep. 18, 2018	Mar. 31, 2017	Sep. 30, 2020	Jun. 30, 2020	Jun. 30, 2019
Number of common stock shares issued			473,286
License Agreement [Member]
Value of common stock shares				$ 35,000
Impairment of licenses					$ 367,915
Kotzker Consulting LLC [Member]
Due to related party		$ 180,000
Payment of patent prosecution costs		$ 15,000
Number of common stock shares issued		31,550
Value of common stock shares		$ 78,875
Shares issued price per share		$ 2.50
Kotzker Consulting LLC [Member] | License Agreement [Member]
Capitalized legal fees		$ 29,040
Capitalized cost of intangible assets					302,915
Accu-Break Pharmaceuticals, Inc. [Member]
Payment to license	$ 35,000			$ 35,000	30,000
Accu-Break Pharmaceuticals, Inc. [Member] | License Agreement [Member]
Capitalized cost of intangible assets					$ 65,000

Stockholders' Equity (Details N

Stockholders' Equity (Details Narrative) - USD ($)

Oct. 26, 2018

Oct. 17, 2018

Oct. 02, 2018

Sep. 30, 2018

Aug. 19, 2018

Aug. 10, 2017

Aug. 31, 2018

Jul. 31, 2018

Mar. 31, 2018

Sep. 30, 2020

Sep. 30, 2019

Dec. 31, 2018

Jun. 30, 2020

Jun. 30, 2019

Jul. 25, 2018

Mar. 30, 2018

Number of common stock shares issued

473,286

Value of common stock shares issued for services

$ 7,500

Number of common stock shares issued for settlement of accounts payable

15,000

Share based compensation stock options, vested

5,233,333

Fair value of stock option, vested

$ 654,167

$ 654,167

Stockholder's equity

$ (7,480)

183,561

$ (6,365)

$ 265,920

Options exercisable term

5 years 6 months

Number of shares forfeited unvested

150,000

Number of shares forfeited unvested, value

$ 18,750

Number of options issued

5,000,000

2017 Stock Incentive Plan [Member]

Share based compensation stock options, vested

150,000

Fair value of stock option, vested

$ 18,750

2018 Equity Incentive Plan [Member]

Fair value of stock option, vested

$ 33,307

Common stock reserved for issuance

8,000,000

Fair value of stock option granted

$ 867,715

CEO [Member]

Number of common stock shares issued

1,797,192

Stock price per unit

$ 0.014

Conversion of a note payable

$ 25,000

Accrued interest payable

161

Amortization of unvested charges

786,997

$ 578,945

Five Officers and Directors [Member] | 2017 Stock Incentive Plan [Member]

Number of common stock shares issued

6,400,000

Stock price per share

$ 0.125

Value of common stock shares

$ 800,000

Former Chief Executive Officer [Member] | 2017 Stock Incentive Plan [Member]

Unvested forfeited, shares

1,666,667

Unvested forfeited, amount

$ 145,833

Chief Executive Officer and Chief Financial Officer [Member]

Number of unvested shares of common stock

1,083,342

Officers / Directors / Consultants [Member] | 2018 Equity Incentive Plan [Member]

Number of options to purchase shares of common stock

1,810,000

Options exercisable term

7 years

Options exercise price per share

$ 0.54

Two Individuals [Member] | 2018 Equity Incentive Plan [Member]

Number of options to purchase shares of common stock

150,000

Options exercisable term

7 years

Options exercise price per share

$ 0.38

Officers / Directors [Member] | 2018 Equity Incentive Plan [Member]

Number of options to purchase shares of common stock

800,000

500,000

Options exercisable term

7 years

7 years

Options exercise price per share

$ 0.655

$ 0.48

Board of Directors [Member] | 2018 Equity Incentive Plan [Member]

Share based compensation stock options, vested

1,666,666

3,333,334

Fair value of stock option granted

248,144

Number of options issued

5,000,000

Options exercisable

$ 0.08

Consulting Services [Member]

Number of common stock shares issued for services

16,667

Value of common stock shares issued for services

$ 1,500

Stock price per share

$ 0.09

CRX Limited Liability Company [Member]

Value of vested shares issued and amortization of unvested shares

$ 4,574,234

$ 3,787,237

CRX Limited Liability Company [Member] | October 26, 2019 [Member]

Share based compensation vesting percentage

30.00%

Share based compensation vesting period

12 months

CRX Limited Liability Company [Member] | October 26, 2020 [Member]

Share based compensation vesting percentage

30.00%

Share based compensation vesting period

24 months

CRX Limited Liability Company [Member] | October 26, 2021 [Member]

Share based compensation vesting percentage

30.00%

Share based compensation vesting period

36 months

Investors Relations Contract [Member] | As Partial Consideration [Member]

Number of common stock shares issued

75,000

Stock price per share

$ 0.10

Value of common stock shares

$ 7,500

License Agreement [Member]

Value of common stock shares

$ 35,000

License Agreement [Member] | For Final Payment [Member]

Number of common stock shares issued

381,619

Stock price per share

$ 0.092

Value of common stock shares

$ 35,000

Interest Purchase Agreement [Member] | CRX Limited Liability Company [Member]

Number of common stock shares issued

11,000,000

Stock price per share

$ 0.76

Fair value of common stock issued for asses acquisition

$ 0

Number of common stock restricted shares forfeited

1,100,000

Share based compensation stock options, vested

9,900,000

Fair value of shares issued

$ 8,360,000

$ 836,000

Number of common stock restricted shares

11,000,000

Fair value of stock option, vested

$ 7,524,000

Stockholder's equity

$ 0

Interest Purchase Agreement [Member] | CRX Limited Liability Company [Member] | Restricted Stock [Member]

Stock price per share

$ 0.76

Number of common stock restricted shares forfeited

1,100,000

Stockholders' Equity - Schedule

Stockholders' Equity - Schedule of Fair Value of Stock Options Assumptions (Details) - 2018 Equity Incentive Plan [Member]	Oct. 17, 2018	Aug. 31, 2018	Aug. 19, 2018
Average risk-free interest rates, Minimum	2.88%	2.30%
Average risk-free interest rates, Maximum	2.93%	2.80%
Average risk-free interest rates			0.23%
Average expected life (in years)	4 years		4 years
Volatility, Minimum	171.00%	160.00%
Volatility, Maximum	172.00%	296.00%
Volatility			152.00%
Minimum [Member]
Average expected life (in years)		4 years
Maximum [Member]
Average expected life (in years)		7 years

Stockholders' Equity - Schedu_2

Stockholders' Equity - Schedule of Stock Option Activity (Details)	3 Months Ended
	Sep. 30, 2020$ / sharesshares
Equity [Abstract]
Number of shares, Outstanding and exercisable beginning balance	2,995,000
Number of shares, Granted	5,000,000
Number of shares, Exercised
Number of shares, Expired/Canceled
Number of shares, Outstanding ending balance	7,995,000
Number of shares, Exercisable ending balance	6,745,001
Weighted Average Exercise Price, Outstanding and exercisable beginning balance | $ / shares	$ 0.55
Weighted Average Exercise Price, Granted | $ / shares	0.08
Weighted Average Exercise Price, Outstanding and Exercisable ending balance | $ / shares	0.26
Weighted Average Exercise Price, Exercisable ending balance | $ / shares	$ 0.31
Weighted Average Remaining Contractual Life (Years), Outstanding and Exercisable beginning balance	5 years 2 months 12 days
Weighted Average Remaining Contractual Life (Years), Granted	6 years 10 months 25 days
Weighted Average Remaining Contractual Life (Years), Outstanding ending balance	5 years 6 months
Weighted Average Remaining Contractual Life (Years), Exercisable ending balance	5 years 6 months

Convertible Note Payable - Rela

Convertible Note Payable - Related Party (Details Narrative)	Aug. 12, 2020USD ($)$ / sharesshares	Jun. 11, 2020USD ($)d$ / shares	Jul. 10, 2020USD ($)	Jun. 30, 2020USD ($)
Accrued interest				$ 33
Chief Executive Officer [Member]
Lending amount	$ 25,000
Accrued interest	$ 161
Loans payable			$ 13,000
Conversion of shares | shares	1,797,192
Conversion price | $ / shares	$ 0.014
Financing Arrangement [Member] | Chief Executive Officer [Member]
Debt interest rate		5.00%
Closing price per share | $ / shares		$ 0.014
Trading days | d		10
Financing Arrangement [Member] | Chief Executive Officer [Member] | Maximum [Member]
Lending amount		$ 25,000
Financing Arrangement [Member] | Lender [Member]
Advance amount				$ 12,000

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	Jun. 30, 2020	Aug. 10, 2017	Mar. 31, 2018	Sep. 30, 2020	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2017
Number of common stock shares issued				473,286
Repaid to related party					$ 9,000	$ 15,000
Number of shares cancelled unvested						150,000
Number of shares vested				$ 654,167	654,167
2017 Stock Incentive Plan [Member]
Number of shares vested					18,750
2017 Stock Incentive Plan [Member] | Five Officers and Directors [Member]
Number of common stock shares issued		6,400,000
Value of common stock shares issued		$ 800,000
Stock price per share		$ 0.125
Stock option plan description		One-third of each grant vested as of the initial date of grant (August 10, 2017), and 8-1/3% upon the end of each calendar quarter beginning December 31, 2017.
2017 Stock Incentive Plan [Member] | Chief Executive Officer [Member]
Number of shares cancelled unvested			1,166,667
Kanativa Inc [Member]
Number of common stock shares issued				24,000,000
Ownership percentage				100.00%
Cost and expenses				$ 201,228
Value of common stock shares issued				172,915
Repaid to related party	$ 50,662
Repayments of debt	$ 90,667
Debt maturity date	Mar. 1, 2020
Write-off of remaining balance					$ 90,667
Kotzker Consulting [Member]
Value of common stock shares issued				78,875
Legal cost				$ 94,040
Kanativa USA [Member]
Due from related parties							$ 141,329

Subsequent Event (Details Narra

Subsequent Event (Details Narrative)	Oct. 02, 2020USD ($)
Subsequent Event [Member] | Chief Executive Officer [Member]
Working capital	$ 15,000